Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Structural basis of the atypical activation mechanism of KRAS V14I.

Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD.

J Biol Chem. 2019 Jul 24. pii: jbc.RA119.009131. doi: 10.1074/jbc.RA119.009131. [Epub ahead of print]

2.

Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.

Peng H, Zhang Y, Zhou Z, Guo Y, Huang X, Westover KD, Zhang Z, Chen B, Hua Y, Li S, Xu R, Lin N, Peng B, Shen S.

EBioMedicine. 2019 Aug;46:105-118. doi: 10.1016/j.ebiom.2019.07.002. Epub 2019 Jul 16.

3.

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.

Jin H, Jang Y, Cheng N, Li Q, Cui PF, Zhou ZW, Jiang HL, Cho MH, Westover KD, Tan QY, Xu CX.

J Exp Clin Cancer Res. 2019 Apr 15;38(1):165. doi: 10.1186/s13046-019-1170-7.

4.

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.

Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS.

Cell Chem Biol. 2019 Jun 20;26(6):818-829.e9. doi: 10.1016/j.chembiol.2019.02.021. Epub 2019 Apr 11.

PMID:
30982749
5.

Tissue-Specific Oncogenic Activity of KRASA146T.

Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM.

Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5.

PMID:
30952657
6.

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.

Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS.

Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10. doi: 10.1016/j.chembiol.2019.02.012. Epub 2019 Mar 21.

PMID:
30905681
7.

Automated Text Message Reminders Improve Radiation Therapy Compliance.

Tan J, Christie A, Montalvo SK, Wallace C, Yan Y, Folkerts M, Yingling A, Sher D, Choy H, Jiang S, Westover KD.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1045-1052. doi: 10.1016/j.ijrobp.2018.11.050. Epub 2018 Nov 30.

PMID:
30508618
8.

GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level.

Li Q, Wei X, Zhou ZW, Wang SN, Jin H, Chen KJ, Luo J, Westover KD, Wang JM, Wang D, Xu CX, Shan JL.

Cell Death Dis. 2018 May 1;9(5):524. doi: 10.1038/s41419-018-0452-x.

9.

Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer.

Hao H, Zhou Z, Li S, Maquilan G, Folkert MR, Iyengar P, Westover KD, Albuquerque K, Liu F, Choy H, Timmerman R, Yang L, Wang J.

Phys Med Biol. 2018 May 2;63(9):095007. doi: 10.1088/1361-6560/aabb5e.

10.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Ambrogio C, Köhler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaría D, Westover KD, Jänne PA.

Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.

11.

KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation.

Lu J, Bera AK, Gondi S, Westover KD.

Biochemistry. 2018 Jan 23;57(3):324-333. doi: 10.1021/acs.biochem.7b00974. Epub 2017 Dec 28.

PMID:
29235861
12.

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD.

JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11.

13.

Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease.

Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER.

Cell Chem Biol. 2017 Aug 17;24(8):1029-1039.e7. doi: 10.1016/j.chembiol.2017.07.011.

14.

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS.

Cell Chem Biol. 2017 Aug 17;24(8):1005-1016.e3. doi: 10.1016/j.chembiol.2017.06.017. Epub 2017 Aug 3.

15.

KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.

Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD.

Structure. 2017 Sep 5;25(9):1442-1448.e3. doi: 10.1016/j.str.2017.07.003. Epub 2017 Aug 3.

16.

Covalent Guanosine Mimetic Inhibitors of G12C KRAS.

Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS.

ACS Med Chem Lett. 2016 Nov 30;8(1):61-66. doi: 10.1021/acsmedchemlett.6b00373. eCollection 2017 Jan 12.

17.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS.

Bioorg Med Chem. 2017 Feb 15;25(4):1320-1328. doi: 10.1016/j.bmc.2016.11.034. Epub 2016 Dec 7.

18.

Structure-guided development of covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS.

Bioorg Med Chem. 2017 Feb 1;25(3):838-846. doi: 10.1016/j.bmc.2016.11.035. Epub 2016 Dec 9.

19.

Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.

Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD.

J Biol Chem. 2017 Jan 6;292(1):112-120. doi: 10.1074/jbc.M116.750299. Epub 2016 Nov 21.

20.

Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching.

Harrison RA, Lu J, Carrasco M, Hunter J, Manandhar A, Gondi S, Westover KD, Engen JR.

J Mol Biol. 2016 Nov 20;428(23):4723-4735. doi: 10.1016/j.jmb.2016.10.017. Epub 2016 Oct 14.

21.

Rationale for RAS mutation-tailored therapies.

Montalvo SK, Li L, Westover KD.

Future Oncol. 2017 Feb;13(3):263-271. doi: 10.2217/fon-2016-0363. Epub 2016 Oct 12. Review.

PMID:
27728979
22.

Corrigendum: A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.

Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu MR, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM.

Nat Chem Biol. 2016 Jul 19;12(8):656. doi: 10.1038/nchembio0816-656. No abstract available.

PMID:
27434767
23.

Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.

Hwang SY, Deng X, Byun S, Lee C, Lee SJ, Suh H, Zhang J, Kang Q, Zhang T, Westover KD, Mandinova A, Lee SW.

Cell Rep. 2016 Jun 28;16(1):28-36. doi: 10.1016/j.celrep.2016.05.071. Epub 2016 Jun 16.

24.

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.

Xia Y, Li Y, Westover KD, Sun J, Chen H, Zhang J, Fisher DE.

PLoS One. 2016 May 6;11(5):e0155217. doi: 10.1371/journal.pone.0155217. eCollection 2016.

25.

Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair.

Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD.

Radiat Res. 2016 May;185(5):527-38. doi: 10.1667/RR14373.1. Epub 2016 May 2.

26.

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.

Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Vander Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM.

Nat Chem Biol. 2016 Jun;12(6):452-8. doi: 10.1038/nchembio.2070. Epub 2016 Apr 25. Erratum in: Nat Chem Biol. 2016 Jul 19;12 (8):656.

27.

Structural dataset for the fast-exchanging KRAS G13D.

Lu J, Hunter J, Manandhar A, Gurbani D, Westover KD.

Data Brief. 2015 Oct 17;5:572-8. doi: 10.1016/j.dib.2015.10.001. eCollection 2015 Dec.

28.

Progress on Covalent Inhibition of KRAS(G12C).

Westover KD, Jänne PA, Gray NS.

Cancer Discov. 2016 Mar;6(3):233-4. doi: 10.1158/2159-8290.CD-16-0092.

29.

Data publication with the structural biology data grid supports live analysis.

Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Fromme JC, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P.

Nat Commun. 2016 Mar 7;7:10882. doi: 10.1038/ncomms10882.

30.

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Westover KD, Loo BW Jr, Gerber DE, Iyengar P, Choy H, Diehn M, Hughes R, Schiller J, Dowell J, Wardak Z, Sher D, Christie A, Xie XJ, Corona I, Sharma A, Wadsworth ME, Timmerman R.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81. doi: 10.1016/j.ijrobp.2015.05.004. Epub 2015 May 9.

PMID:
26279026
31.

Development of small molecules targeting the pseudokinase Her3.

Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3382-9. doi: 10.1016/j.bmcl.2015.04.103. Epub 2015 May 11.

32.

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD.

Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.

33.

SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.

Westover KD, Iyengar P, Sharma AN, Timmerman R.

Lung Cancer. 2015 Aug;89(2):87-93. doi: 10.1016/j.lungcan.2015.04.009. Epub 2015 May 8. Review.

PMID:
26028304
34.

Pharmacological targeting of the pseudokinase Her3.

Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658. Epub 2014 Oct 19.

35.

Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.

Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R.

J Thorac Oncol. 2015 Feb;10(2):280-5. doi: 10.1097/JTO.0000000000000399.

36.

Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).

Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS.

J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30.

37.

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.

Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8895-900. doi: 10.1073/pnas.1404639111. Epub 2014 Jun 2.

38.

Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.

Laine AM, Westover KD, Choy H.

Semin Oncol. 2014 Feb;41(1):57-68. doi: 10.1053/j.seminoncol.2013.12.012. Epub 2013 Dec 12. Review.

PMID:
24565581
39.

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS.

Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. doi: 10.1002/anie.201307387. Epub 2013 Nov 20.

40.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.

Cancer Res. 2013 Apr 15;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. Epub 2013 Feb 22.

41.

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S.

Cell. 2012 Aug 31;150(5):987-1001. doi: 10.1016/j.cell.2012.06.047.

42.

Proton SBRT for medically inoperable stage I NSCLC.

Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H.

J Thorac Oncol. 2012 Jun;7(6):1021-5. doi: 10.1097/JTO.0b013e31824de0bf.

43.

Should a sentinel node biopsy be performed in patients with high-risk breast cancer?

Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS.

Int J Breast Cancer. 2011;2011:973245. doi: 10.4061/2011/973245. Epub 2011 Aug 10.

44.

Significance testing as perverse probabilistic reasoning.

Westover MB, Westover KD, Bianchi MT.

BMC Med. 2011 Feb 28;9:20. doi: 10.1186/1741-7015-9-20.

45.

Comprehensive and efficient HBB mutation analysis for detection of beta-hemoglobinopathies in a pan-ethnic population.

Chan OT, Westover KD, Dietz L, Zehnder JL, Schrijver I.

Am J Clin Pathol. 2010 May;133(5):700-7. doi: 10.1309/AJCP7HQ2KWGHECIO.

PMID:
20395516
46.

Structural basis of transcription: backtracked RNA polymerase II at 3.4 angstrom resolution.

Wang D, Bushnell DA, Huang X, Westover KD, Levitt M, Kornberg RD.

Science. 2009 May 29;324(5931):1203-6. doi: 10.1126/science.1168729.

47.

Structural basis of transcription: role of the trigger loop in substrate specificity and catalysis.

Wang D, Bushnell DA, Westover KD, Kaplan CD, Kornberg RD.

Cell. 2006 Dec 1;127(5):941-54.

48.

Structural basis of eukaryotic gene transcription.

Boeger H, Bushnell DA, Davis R, Griesenbeck J, Lorch Y, Strattan JS, Westover KD, Kornberg RD.

FEBS Lett. 2005 Feb 7;579(4):899-903. Review.

49.

Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center.

Batada NN, Westover KD, Bushnell DA, Levitt M, Kornberg RD.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17361-4. Epub 2004 Dec 1.

50.

Structural basis of transcription: nucleotide selection by rotation in the RNA polymerase II active center.

Westover KD, Bushnell DA, Kornberg RD.

Cell. 2004 Nov 12;119(4):481-9. Erratum in: Cell.2004 Dec 29;119(7):1055.

Supplemental Content

Loading ...
Support Center